The methods and compositions comprise the administration of a composition comprising one or more cannabinoids and/or one or more terpenes.

DENVER, COLORADO, USA, July 11, 2017 /EINPresswire.com/ -- INTIVA BioPharma Inc. has filed a provisional patent application with the United States Patent Office describing methods and compositions for treating Restless Legs Syndrome. The methods comprise the administration of a composition comprising one or more cannabinoids and/or one or more terpenes.

Restless legs syndrome (RLS), otherwise known as Willis-Ekbom Disease, and Wittmaack-Ekbom syndrome, is a term used to describe a neurological sensory disorder that also interferes with sleep and is thus also considered a sleep disorder.

The symptoms of RLS include the compelling, irresistible, or uncontrollable urge to move, restlessness, and abnormal, unpleasant, or uncomfortable sensations in the limbs or the skin
of the feet, legs, arms, or elsewhere which include pain, aching, throbbing, pulling, itching,
crawling, creeping, burning, jerking, fidgety, antsy, electrical, pins and needles, buzzing, and twitching. The movements may be persistent, repetitive, periodic, or intermittent with symptoms
in remission for periods of time. Clinical manifestations appear mainly in the evening or nighttime, sometimes peaking between the hours of 12:00 AM to 4:00 AM. They can also manifest during periods of relaxation, rest, inactivity, or by lying or sitting down for a period of time.

RLS is believed to be related to dysfunction in the basal ganglia section of the brain that controls movement and that uses dopamine. This dysfunction is thought to be similar to the dopamine dysfunction of Parkinson’s disease. There are also a number of factors or conditions that are linked to RLS which include iron deficiency, pregnancy, certain medications such as anticonvulsants, antidepressants, beta-blockers, antipsychotics, certain substances such as alcohol, caffeine, cigarettes, neuropathy, venous disorders, renal disease and failure, sleep disorders, genetic inheritance, fibromyalgia, vitamin and mineral deficiencies, amyloidosis, hyper or hypothyroidism, Lyme disease, arthritis, diabetes mellitus, Periodic Limb Movement Disorder (PLMD) and Parkinson’s disease.

Robert Goldfarb, COO of INTIVA BioPharma, stated, “There is no known cure for RLS. Treatment options include treating the associated factors or conditions and physical measures, but most treatment options are futile resulting in progressively worsening clinical manifestations and which may eventually lead to insomnia. Lack of sleep due to RLS contributes to an impairment in life quality and an increase in depressive disorders, anxiety, and the occurrence of panic attacks. Patients with RLS sometimes use treatment options that include dopamine agonists, opiates, or anticonvulsants or a combination thereof, however most patients halt treatment due to the poor efficacy or harmful side effects. There is a need for improved treatments of RLS, and we’re hopeful of the prospects of a drug consisting of cannabinoids and/or terpenes being successful in treating some of the symptoms of RLS.”

INTIVA BioPharma has assembled a team of experienced professionals in pharmaceutical development and regulatory compliance for its drug development activities.

About INTIVA BioPharma Inc.

INTIVA BioPharma is proceeding with pre-clinical and clinical drug development activities, in accordance with U.S. Food and Drug Administration ("FDA") protocols, for a number of pharmaceutical formulations that include cannabinoids.
BioPharma’s drug development strategy consists of:
The determination of medical conditions and disorders that could potentially benefit from cannabinoid-based formulations;
Conducting “freedom to operate” investigations on these conditions;
The preparation of patent applications and the prosecution of such application and/or the licensing of existing patents;
Identifying the regulatory pathway with the U.S. Food and Drug Administration (FDA); and
Proceeding with pre-clinical and clinical development activities in accordance with FDA protocols for submission to obtain approval for the particular product(s).

INTIVA BioPharma website: www.intivabiopharma.com.

INTIVA Disclosure Notice: This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “would,” “estimate,” or “continue,” or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Readers are cautioned that all forward-looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; the Company’s ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of the Company’s control.

Readers are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. The Company undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.

Contact
Jeffrey Friedland
Chief Executive Officer
INTIVA BioPharma Inc.
Tel. 1-800-497-2915
Email IntivaBioPharma@intiva.us
Website www.INTIVABioPharma.com

Jeffrey Friedland
INTIVA BioPharma Inc.
800 497 2915
email us here